ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
06 Novembre 2024 - 10:00PM
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma
company focused on accelerating the development and delivery of
transformative medicines in immunology, today announced it will
host a conference call on Wednesday, November 13, 2024 at 4:30 p.m.
ET to discuss its third quarter 2024 financial results and other
corporate updates.
A live webcast of the conference call will be available on the
Company’s website under Events & Presentations. A replay
of the webcast will be available on the Company’s website for 90
days.
About ACELYRINACELYRIN, INC. (Nasdaq: SLRN) is
focused on providing patients life-changing new treatment options
by identifying, acquiring, and accelerating the development and
commercialization of transformative medicines. ACELYRIN’s lead
program, lonigutamab, is a subcutaneously delivered monoclonal
antibody targeting IGF-1R being investigated for the treatment of
thyroid eye disease.
For more information about ACELYRIN, visit us at
www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements Some statements in
this press release are, or may be considered, forward-looking
statements, including statements regarding ACELYRIN’s progress,
business plans and clinical trials, as well as the potential future
benefits of our product candidates. While ACELYRIN, INC. considers
any projections to be based on reasonable assumptions, these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
anticipated in such forward-looking statements.
ACELYRIN Contacts:Tyler
MarciniakVice President of Investor Relations and Corporate
Affairsinvestors@acelyrin.com media@acelyrin.com
ACELYRIN (NASDAQ:SLRN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
ACELYRIN (NASDAQ:SLRN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024